China, 2025
+4.1%since 2024
Source: World Bank
CHN · Country · 38 publishers
China statistics
1,967 verified figures for China across 23 industries and 567 measures, 1960–2040, from 38 publishers.
Inflation, consumer prices (annual %)
0.06%China, 2025
−0.2 ppsince 2024
Source: World Bank
Mobile-cellular subscriptions per 100 inhabitants
130 per 100 inhabitantsChina, 2025
−1.3%since 2024
Source: MIIT
DTP3 immunization coverage among 1-year-olds (%)
97%China, 2025 Estimate
0 ppsince 2024
Source: WHO
Key findings
Drawn from every industry that publishes a figure for China.
- Electronic information manufacturing sector revenue in China was 17.4 trillion CNY in 2025 (MIIT). MIIT ↗ T1 Official
- Online retail sales of goods in China (year to date) were 13,081.6 billion CNY in 2024 (NBS China). NBS China ↗ T1 Official
- Online retail sales of goods and services in China (year to date) were 15,522.5 billion CNY in 2024 (NBS China). NBS China ↗ T1 Official
- Semiconductor materials market revenue in China was 15.6 billion USD in 2025 (SEMI). SEMI ↗ T2 Official
- Telecommunications business revenue in China was 1.75 trillion CNY in 2025 (MIIT). MIIT ↗ T1 Official
- China console game market actual sales revenue was 4.49 billion CNY in 2024 (CADPA). CADPA ↗ T2 Official
- China domestic game market actual sales revenue was 325.8 billion CNY in 2024 (CADPA). CADPA ↗ T2 Official
- China esports game market actual sales revenue was 142.9 billion CNY in 2024 (CADPA). CADPA ↗ T2 Official
- China mini-program game market revenue was 39.8 billion CNY in 2024 (CADPA). CADPA ↗ T2 Official
- China mobile game market actual sales revenue was 238.2 billion CNY in 2024 (CADPA). CADPA ↗ T2 Official
China country profile
Latest verified figure for China on each panel indicator, with world and continental rank. Ranks compare countries on one reference year per indicator: the most recent year in which at least half of the countries that have ever reported have a figure. Higher values rank first; ties share a rank. Forecasts and future periods are excluded. The value shown is the latest figure, which may be a later year than the rank. See the methodology.
China statistics by topic
Topic pages for China. Country rankings it appears in are listed below the tiles.
- Economy · 167 records19,498,039,388,042.6USDGDP in China
- Electricity and Gas Utilities · 80 records37%Electricity generation in China
- Retail · 75 records8,419.5 billionCNYRetail sales in China
- Telecommunications · 71 records91.6%Internet users in China
- Pharmaceuticals · 70 records46Clinical trial starts in China
- Pharmaceuticals · 70 records38New drug approvals in China
- Telecommunications · 39 records130per 100 inhabitantsMobile subscriptions in China
- Electricity and Gas Utilities · 36 records12,289 milliontonnesPower sector CO2 emissions in China
- Electricity and Gas Utilities · 29 records526.2gCO2e/kWhCarbon intensity of electricity in China
- Chemicals · 21 records7,487CNY/tonneChemical market prices in China
- Construction · 19 records1,074.1CNY per tonneBuilding material prices in China
- Pharmaceuticals · 16 records199Reimbursement list additions in China
- Electricity and Gas Utilities · 15 records120.5gigawattsPower capacity additions in China
- Chemicals · 14 records8,450CNY/tonnePolyester filament price in China
- Chemicals · 13 records12,572.2CNY/tonneButadiene rubber price in China
- Food and Beverage · 13 records4,696.7CNY/tonneSoybean price in China
- Chemicals · 12 records684.8CNY/tonneCaustic soda price in China
- Chemicals · 12 records8,929CNY/tonnePolypropylene price in China
- Chemicals · 12 records1,983.7CNY/tonneSulfuric acid price in China
- Electric Vehicles · 11 records35%Electric vehicle sales in China
- Pharmaceuticals · 11 records2,218Clinical trial registrations in China
- Electric Vehicles · 10 records13 millionElectric car sales in China
- Pharmaceuticals · 10 records3,253Drugs on reimbursement lists in China
- Steel and Basic Metals · 8 records74.6 millionmillion tonnesCrude steel production in China
- Electricity and Gas Utilities · 7 records7%Electricity demand in China
- Chess · 5 records4,086FIDE rated chess players in China
- Chess · 5 records57Chess grandmasters and titled players in China
- Semiconductors · 5 records123.6%Semiconductor sales in China
- Electricity and Gas Utilities · 4 records300GWPower generation capacity in China
- Steel and Basic Metals · 4 records153%Steel exports in China
- Healthcare · 4 records84Oncology drug launches in China
- Food and Beverage · 4 records-15.5CNY/tonWheat price in China
- Insurance · 3 records12.5%Insurance premiums in China
- Electricity and Gas Utilities · 3 records93.4%Wind turbine installations by manufacturer in China
- Pharmaceuticals · 3 records15%Clinical trial locations by country in China
- Chemicals · 3 records3.6 milliontonnesChemical production in China
Where China ranks
- Internet use share by country #46 of 182 · 92% · 2024
- Crude steel production by country #1 of 8 · 84.4 million tonnes · May 2026
- New wind power capacity by country #1 of 5 · 120.5 gigawatts · 2025
- Electric car sales share by country #1 of 6 · 35% · 2023
- Carbon intensity of electricity by country #68 of 191 · 556.3 gCO2e/kWh · 2024
- Life expectancy at birth by country #65 of 210 · 78 years · 2024
- Data-only mobile broadband basket price as share of GNI per capita by country #184 of 201 · 0.25% · 2025
- FIDE standard-rated players by country #35 of 200 · 4,091 · October 2026
- FIDE standard-rated female players by country #11 of 194 · 1,071 · October 2026
- Current health expenditure (CHE) as percentage of GDP (%) by country #105 of 192 · 5.94% · 2023
- Domestic general government health expenditure as percentage of GDP (%) by country #88 of 192 · 3.39% · 2023
- Renewable share of electricity generation by country #90 of 192 · 33.7% · 2024
- Current health expenditure (CHE) per capita (US$) by country #71 of 191 · 763.4 USD · 2023
- Solar share of electricity generation by country #54 of 191 · 8.32% · 2024
- Fixed broadband basket price as share of GNI per capita by country #187 of 190 · 0.38% · 2025
- Wind power share of electricity mix by country #33 of 189 · 9.88% · 2024
- GDP (current US$) by country #2 of 185 · 19,498,039,388,042.6 USD · 2025
- GDP per capita, PPP (current international $) by country #69 of 184 · 29,333.3 current international $ · 2025
- Inflation, consumer prices (annual %) by country #157 of 169 · 0.06% · 2025
- FIDE Masters (standard list) by country #45 of 166 · 42 · October 2026
- Mobile-cellular subscriptions per 100 inhabitants by country #44 of 151 · 131.8 per 100 inhabitants · 2024
- FIDE International Masters (standard list) by country #17 of 123 · 60 · October 2026
- Government expenditure on education (% of GDP) by country #54 of 119 · 3.9% · 2023
- School enrollment, tertiary (% gross) by country #20 of 94 · 76.9% · 2024
- FIDE Grandmasters (standard list) by country #9 of 89 · 57 · October 2026
- FIDE Woman Grandmasters (standard list) by country #2 of 63 · 31 · October 2026
- Median fixed broadband download speed by country #24 of 25 · 237.6 Mbps · June–August 2026
- Median mobile download speed by country #12 of 25 · 176.2 Mbps · August 2026
- FIDE players rated 2200+ by country #15 of 16 · 333 · September 2026
- FIDE rated juniors (born 2008 or later) by country #11 of 12 · 2,316 · September 2026
- Electric cars as a share of new car sales by country #1 of 5 · 55% · 2025
China by industry
Every measure published for China, grouped by industry, with its latest value and
trend. Region code CN is the same in every industry and in the API.
Healthcare 24
Show 19 more measures
- Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) 95%
- Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 94%
- Current health expenditure (CHE) as percentage of GDP (%) 5.94%
- Current health expenditure (CHE) per capita (US$) 763.4 USD
- Domestic general government health expenditure as percentage of GDP (%) 3.39%
- NCD mortality rate (per 100,000 population) 491.4 per 100,000 people
- Premature NCD mortality probability (ages 30–70, %) 15.9%
- Suicide mortality rate (per 100,000 population) 6.83 per 100,000 people
- Tobacco use prevalence (ages 15+, age-standardized, %) 22.8%
- Tobacco use prevalence: female (ages 15+, age-standardized, %) 1.5%
- Tobacco use prevalence: male (ages 15+, age-standardized, %) 44.2%
- Oncology novel active substance (NAS) launches (cumulative) 84
- Change in regional share of global clinical trial country uses 57%
- Domestic-only oncology NAS launches (cumulative) 45
- Health care and medical services price index growth rate 2.7%
- Manufacture of medicines producer price index growth rate (monthly) -0.2%
- Medicine use index (2020=100) 100 index
- Novel active substances launched exclusively in China 30
- Pharmaceutical manufacturing investment growth rate -9.8%
Economy 10
GDP per capita, PPP (current international $) 29,333.3 current international $ +8.1% since 2024 World Bank 36 records
Show 5 more measures
Electricity and Gas Utilities 57
Show 52 more measures
- Wind power share of electricity mix 10.7%
- Polysilicon price 40.9 CNY/kg
- Polysilicon price change 0.4 CNY/kg
- Polysilicon price growth rate 1%
- Electricity demand growth 7%
- Lithium iron phosphate market price 55,800.8 CNY/ton
- Lithium iron phosphate price growth rate 1.4%
- Carbon intensity of electricity generation annual decline rate 5%
- China's share of PV manufacturing capacity by 2030 80%
- Chinese OEMs' domestic installation share 93.4%
- Chinese suppliers among top 15 global wind turbine suppliers 9
- Chinese suppliers' share of Chinese wind turbine market 100%
- Chinese wind turbine capacity installed outside China 9,319 MW
- Country share of global renewable capacity expansion 40%
- Electricity generation CO2 emissions annual change rate 1%
- Electricity, heat, gas and water utility total profits 478.4 billion CNY
- Electricity, heat, gas and water utility total profits growth rate -5.8%
- Hydropower capacity under construction 300 GW
- Liquefied natural gas market price 5,572.8 CNY per tonne
- Liquefied natural gas wholesale price 5,724.6 CNY per tonne
- Lithium iron phosphate price 56,114.5 CNY/tonne
- Lithium iron phosphate price change 2,382 CNY/tonne
- Lithium iron phosphate price change (CNY/ton) -1,104.6 CNY/ton
- Lithium iron phosphate price change (ton) 790.9 CNY per tonne
- Lithium iron phosphate price change rate -1.9%
- New hydropower capacity added 14.4 GW
- New pumped storage hydropower capacity added 7.75 GW
- New wind power capacity installed 120.5 gigawatts
- Nuclear electricity generation growth 6%
- Producer price index for electricity and heat power production and supply year-on-year growth rate -3.6%
- Producer price index for gas production and supply year-on-year growth rate 4.2%
- Pumped storage capacity commissioned 7,500 MW
- Pumped storage capacity under construction 218 GW
- Share of electricity consumption 28%
- Share of electricity demand growth 50%
- Share of global hydropower capacity additions 40%
- Share of global new renewable capacity added 60%
- Share of global new wind and solar PV capacity installed in China 33.3%
- Share of global renewable capacity expansion to 2030 60%
- Share of global renewable capacity growth 40%
- Share of global solar cell manufacturing capacity 60%
- Share of global solar PV capacity expansion 50%
- Share of global solar PV demand 50%
- Share of renewable capacity additions increase by country 30%
- Share of renewable capacity installations 60%
- Share of renewable power capacity 50%
- Share of renewable power capacity (annual) 33.3%
- Solar PV share of electricity generation 10%
- Wind and solar PV capacity additions growth rate 30%
- Wind turbine capacity commissioned 120 GW
- Wind turbine capacity installed 130 GW
- Wind turbines installed 18,291
Pharmaceuticals 112
Show 107 more measures
- Cardiometabolic RNA and next-generation lipid drug trial starts 35
- Gene editing trial starts 54
- GLP-1, incretin multi-agonist and amylin trial starts 178
- Inflammatory bowel disease drug trial starts 101
- KRAS and RAS inhibitor trial starts 91
- Oncology bispecific antibody trial starts 489
- Radioligand therapy trial starts 75
- Innovative drug approvals 76
- Innovative drug out-licensing deal value 130 billion USD
- Innovative drug out-licensing deal count 157
- Clinical trial country use share 15%
- Innovative drug out-licensing deal value (half year) 110 billion USD
- Newly added drugs in national reimbursement drug list 114
- Pediatric medicine approvals 106
- Rare disease medicine approvals 55
- Approved innovative drugs designated as breakthrough therapies 13
- Beneficiaries of negotiated reimbursement drugs 830 million person-visits
- Domestic first-in-class drug approvals 4
- Domestic innovative biological product approvals 21
- Domestic innovative chemical drug approvals 38
- Domestic innovative drug approvals (half year) 31
- Domestic share of approved innovative biological products 91.3%
- Domestic share of approved innovative chemical drugs 80.8%
- Drug approval applications completed under priority review 110
- Drugs in commercial health insurance innovative drug catalog 19
- Drugs removed from national reimbursement drug list 29
- Imported innovative biological product approvals 2
- Imported innovative chemical drug approvals 9
- Innovative biological product approvals 23
- Innovative drug approvals (half year) 38
- Innovative drugs added to national health insurance catalog 50
- Innovative drugs approved via priority review pathway 17
- Innovative drugs granted conditional market approval 11
- Innovative traditional medicine approvals 6
- New drug clinical trials 2,997
- Newly added drugs in national reimbursement drug list (annual) 114
- Pharmaceutical export delivery value growth (half year) 9%
- Pharmaceutical value-added industrial output growth (half year) 6.4%
- Priority review drug approval applications completed growth rate 29%
- Share of global biopharmaceutical pipeline 30%
- Alzheimer's disease innovative drug clinical trial approvals (multi-year total) 8
- Antibody-drug conjugate approvals 3
- Approved Class 1 innovative drugs 76
- Approved Class 1 innovative drugs (half year) 38
- Approved drug marketing registration applications (half year) 2,318
- Approved innovative drugs growth rate 58.3%
- Approved innovative drugs with new targets or mechanisms 11
- Approved innovative drugs with new targets or mechanisms (half year) 11
- Approved novel drugs in breakthrough therapy programs 13
- Bioequivalence trials 2,218
- Bioequivalence trials share 42.5%
- Bispecific antibody approvals 4
- Breast cancer drug approvals 9
- Category 1 innovative drugs added to national health insurance catalog 50
- Cell therapy approvals 3
- Centralized procurement drugs added to national reimbursement drug list 2
- Class 1 innovative drug clinical trials 2,171
- Class 1 innovative drug clinical trials growth rate 4.1%
- Class 1 innovative drug clinical trials share 72.4%
- Clinical trial registrations growth rate 6.4%
47 further measures are in the Pharmaceuticals page.
Telecommunications 42
Mobile-cellular subscriptions per 100 inhabitants 130 per 100 inhabitants −1.3% since 2024 MIIT 36 records
Fixed broadband subscriptions per 100 inhabitants 47.2 per 100 inhabitants +5.5% since 2023 ITU 25 records
Data-only mobile broadband basket price as share of GNI per capita 0.25% −0.2 pp since 2024 ITU 13 records
Show 37 more measures
- China instant-messaging users 1,094 million
- China internet users 1,125 million
- China micro-drama users 664 million
- China mobile internet users 1,121 million
- China online-shopping users 937 million
- China online-video users 1,093 million
- China rural internet users 314 million
- China short-video users 1,074 million
- China urban internet users 812 million
- Internet penetration rate in China 80.1%
- China generative-AI users 602 million
- China livestreaming users 813.6 million
- China livestreaming users as a share of internet users 72.3%
- Rural internet penetration rate in China 69.5%
- 5G base stations 4.84 million
- 5G share of mobile subscriptions 65.9%
- 5G subscriptions 1.2 billion
- Awareness of generative AI in China 331 million
- Cellular IoT connections 2.89 billion
- China long-video users 730 million
- China online food-delivery users 630 million
- China online-education users 327 million
- China online-government-service users 940 million
- China online-healthcare users 411 million
- China online-travel-booking users 548 million
- China senior internet users aged 60+ 161 million
- Elderly internet penetration rate in China 52%
- Fixed broadband subscriptions 691 million
- Generative-AI penetration in China 42.8%
- Gigabit (1000 Mbps and above) broadband subscribers 238 million
- Internet use among adults aged 60+ in China 53.7%
- Median fixed broadband download speed 237.6 Mbps
- Median mobile download speed 176.2 Mbps
- Mobile broadband Internet traffic (annual) 395.8 exabytes
- Mobile-cellular subscriptions 1.83 billion
- Rural fixed broadband subscribers 204 million
- Telecommunications business revenue 1.75 trillion CNY
Chemicals 77
Butadiene rubber (BR9000) market price 12,572.2 CNY/tonne −3.3% since 21 Jul 2026 to 31 Jul 2026 NBS China 3 records
Butadiene rubber (BR9000) market price percent change 6.6% +7.4 pp since 21 Jul 2026 to 31 Jul 2026 NBS China 3 records
Caustic soda (liquid, 32%) market price 684.8 CNY/tonne −0.8% since 21 Jul 2026 to 31 Jul 2026 NBS China 3 records
Show 72 more measures
- Glacial acetic acid (99.5% and above) market price 2,989.2 CNY/tonne
- Glacial acetic acid (99.5% and above) market price change 382.5 CNY/tonne
- Glacial acetic acid (99.5% and above) market price percent change 12.1%
- Lithium iron phosphate (standard power grade) market price 53,732.5 CNY/tonne
- Polyester filament (POY150D/48F) market price 8,450 CNY/tonne
- Polyester filament (POY150D/48F) market price change 312.5 CNY/tonne
- Polyester filament (POY150D/48F) market price percent change 3.5%
- Polypropylene (wire drawing material) market price change 447.3 CNY/tonne
- Pure benzene (industrial grade) market price 7,487 CNY/tonne
- Pure benzene (industrial grade) market price change 935.5 CNY/tonne
- Sulfuric acid (98%) market price 1,983.7 CNY/tonne
- Sulfuric acid (98%) market price change -68.1 CNY/tonne
- Butadiene rubber market price (10-day) 15,112.5 CNY/tonne
- Caustic soda (liquid, 32%) market price percent change 0.2%
- Caustic soda market price (10-day) 682.6 CNY/tonne
- Chemical raw materials and products manufacturing value added growth rate 0%
- Ethanol market price (10-day) 5,355.9 CNY/tonne
- Ethyl alcohol (95.0%) market price 5,487.9 CNY/tonne
- Ethylene production 3.6 million tonnes
- Glacial acetic acid market price (10-day) 3,536.3 CNY/tonne
- Linear low-density polyethylene market price (10-day) 9,239.6 CNY/tonne
- Lithium iron phosphate (standard power grade) market price change -1,598.3 CNY/ton
- Lithium iron phosphate (standard power grade) market price percent change -2.9%
- Methanol market price (10-day) 3,379.1 CNY/tonne
- Methyl alcohol (superior quality) market price 2,526.9 CNY/tonne
- Polyester filament market price (10-day) 9,287.5 CNY/tonne
- Polyethylene (LLDPE) market price 8,500.4 CNY/tonne
- Polypropylene (wire drawing material) market price 8,929 CNY/tonne
- Polypropylene (wire drawing material) market price percent change 0.6%
- Polypropylene market price (10-day) 9,634.4 CNY/tonne
- Pure benzene (industrial grade) market price percent change 2.1%
- Pure benzene market price (10-day) 9,065.2 CNY/tonne
- Sulfuric acid (98%) market price percent change -2.1%
- Sulfuric acid market price (10-day) 1,835.7 CNY/tonne
- Butadiene rubber market price (10-day) (monthly) 13,489.6 CNY per tonne
- Butadiene rubber market price change (10-day) 686.6 CNY/tonne
- Caustic soda market price (10-day) (monthly) 684.5 CNY per tonne
- Caustic soda market price change rate (ten-day) -0.4%
- Chemical industry fixed-asset investment growth rate -7.4%
- Chemical raw materials and products manufacturing fixed-asset investment growth rate -8.1%
- Ethanol (95.0%) market price 5,458.6 CNY/tonne
- Ethanol market price (10-day) (monthly) 5,389.2 CNY per tonne
- Ethanol market price change rate (ten-day) 0.3%
- Ethylene production growth rate 0.1%
- Glacial acetic acid market price (10-day) (monthly) 2,966.7 CNY per tonne
- Glacial acetic acid market price change (10-day) 187.1 CNY/tonne
- Glacial acetic acid market price change rate (10-day) 6.3%
- Linear low-density polyethylene film grade market price 8,413.3 CNY/tonne
- Linear low-density polyethylene market price (10-day) (monthly) 8,602.3 CNY per tonne
- Linear low-density polyethylene market price change rate (ten-day) 5.6%
- Methanol (superior quality) market price 2,479.4 CNY/tonne
- Methanol market price (10-day) (monthly) 2,635.6 CNY per tonne
- Methanol market price change rate (ten-day) 17.6%
- Polyester filament market price (10-day) (monthly) 8,590.6 CNY per tonne
- Polyester filament market price change (10-day) 384.4 CNY/tonne
- Polyester filament market price change rate (10-day) 4.5%
- Polypropylene (wire drawing) market price 8,838.6 CNY/tonne
- Polypropylene market price (10-day) (monthly) 9,034.4 CNY per tonne
- Polypropylene market price change (10-day) 152.7 CNY/tonne
- Polypropylene market price change rate (10-day) 1.7%
12 further measures are in the Chemicals page.
Retail 31
Online retail sales of physical goods share of total retail sales (year to date) 26.8% −0.8 pp since 2023 NBS China 5 records
Show 26 more measures
- Catering industry income 454.4 billion CNY
- Catering industry income growth rate year on year 1.1%
- Retail sales of goods 3,528 billion CNY
- Urban retail sales of consumer goods 3,445.7 billion CNY
- Urban retail sales of consumer goods growth rate year on year 0.2%
- Online retail sales of services (year to date) 5,057.1 billion CNY
- Retail sales of consumer goods excluding automobiles 3,589.2 billion CNY
- Retail sales of consumer goods excluding automobiles growth rate year on year 2.5%
- Retail sales of enterprises above designated size 1,430.8 billion CNY
- Retail sales of enterprises above designated size growth rate year on year -3.4%
- Retail sales of goods growth rate year on year 0.3%
- Retail sales of goods growth rate year on year (year to date) 1%
- Rural retail sales of consumer goods 524.2 billion CNY
- Rural retail sales of consumer goods growth rate year on year 1.6%
- Total retail sales of consumer goods 3,982.4 billion CNY
- Total retail sales of consumer goods (year to date) 32,756.9 billion CNY
- Total retail sales of consumer goods growth rate year on year 0.4%
- Total retail sales of consumer goods growth rate year on year (year to date) 1.1%
- Online retail sales of goods and services growth rate year on year 4.8%
- Online retail sales of services growth rate year on year 5.2%
- Online retail sales of services year-on-year growth 5.1%
- Retail sales of consumer goods in rural areas 536.7 billion CNY
- Retail sales of consumer goods in rural areas year-on-year growth 1.6%
- Retail sales of goods and services year-on-year growth 2.5%
- Retail sales of services growth rate year on year (year to date) 4.9%
- Total retail sales, month-on-month growth -0.13%
Education 4
Literacy rate, adult total (% of people ages 15 and above) 96.7% +1.6 pp since 2010 World Bank 4 records
Food and Beverage 34
Show 29 more measures
- White sugar market price change -17.7 CNY/ton
- Peanut market price change -83.4 CNY/ton
- Soybean market price change rate -0.2%
- Value added growth rate, manufacture of foods 9%
- Value added growth rate, processing of food from agricultural and sideline products 3.8%
- Business revenue growth, processing of food from agricultural and sideline products 2.9%
- Catering services revenue growth rate of enterprises above designated size (monthly) 0%
- Fixed asset investment growth rate, manufacture of foods -9.4%
- Fixed asset investment growth rate, processing of food from agricultural and sideline products -3%
- Japonica rice market price 3,981 CNY/tonne
- Japonica rice market price change 0 CNY/tonne
- Online retail sales growth rate of food (year-to-date) 16.9%
- Online retail sales of food, year-on-year growth 15.9%
- Peanut market price (CNY/tonne) 7,358.3 CNY/tonne
- Soybean market price (CNY/tonne) 4,533.2 CNY/tonne
- Soybean meal market price (CNY/tonne) 3,101.1 CNY/tonne
- Soybean meal market price change 0.8 CNY/ton
- Soybean price change 68.4 CNY/tonne
- Soybean price change rate 1.5%
- Total profits growth, processing of food from agricultural and sideline products -12.3%
- Value added growth of agricultural and sideline food processing 4.3%
- Value added growth of agricultural and sideline food processing (year to date) 4.6%
- Value added growth of food manufacturing 8.8%
- Value added growth of food manufacturing (year to date) 8.5%
- Wheat grade III market price change 0.8 CNY/tonne
- White sugar grade I market price change -29 CNY/ton
- White sugar market price 5,174.2 CNY/ton
- White sugar price change rate 0.5%
- Yellow corn grade II market price change -27.3 CNY/tonne
Construction 43
Float flat glass market price 1,074.1 CNY per tonne −1% since 11 Aug 2026 to 20 Aug 2026 NBS China 2 records
Ordinary Portland cement market price 248.7 CNY per tonne −0.2% since 11 Aug 2026 to 20 Aug 2026 NBS China 2 records
Ordinary Portland cement market price change rate -0.2% −1.1 pp since 11 Aug 2026 to 20 Aug 2026 NBS China 2 records
Show 38 more measures
- Wire market price 3,317.8 CNY per tonne
- Construction business activity expectation index (monthly) 51.8%
- Construction business activity index (monthly) 46.9%
- Construction employment index (monthly) 43%
- Construction input price index (monthly) 51.2%
- Construction new order index (monthly) 42.4%
- Construction sales price index (monthly) 49.8%
- Deposits and advance receipts for real estate development 1,437.6 billion CNY
- Domestic loans for real estate development 630 billion CNY
- Float flat glass market price (snapshot) 1,074.9 CNY per tonne
- Float flat glass market price change 0.8 CNY per tonne
- Float flat glass market price change rate 0.1%
- Floor space of buildings for commercial business for sale 135.3 million square meters
- Floor space of buildings newly started 267 million square meters
- Floor space of buildings newly started growth rate -24%
- Floor space of buildings under construction 5,575.7 million square meters
- Floor space of commercial buildings for sale 759.1 million square meters
- Floor space of newly built commercial buildings sold 450.2 million square meters
- Floor space of newly built residential buildings sold 374.3 million square meters
- Floor space of residential buildings completed 134.4 million square meters
- Floor space of residential buildings newly started 194.9 million square meters
- Floor space of residential buildings under construction 3,870.5 million square meters
- Funds for real estate development 4,574.8 billion CNY
- Individual mortgage loans for real estate development 604 billion CNY
- Investment in commercial business buildings 280.9 billion CNY
- Investment in office buildings 158 billion CNY
- Ordinary hot-rolled sheet market price 3,326.4 CNY per tonne
- Ordinary medium plate market price 3,526.9 CNY per tonne
- Ordinary Portland cement market price (snapshot) 250.7 CNY per tonne
- Ordinary Portland cement market price change 2 CNY per tonne
- Ordinary Portland cement market price change rate (snapshot) 0.8%
- Real estate development investment 4,300.9 billion CNY
- Rebar market price change rate (snapshot) 1.7%
- Residential real estate development investment 3,317.2 billion CNY
- Sales value of newly built commercial buildings 4,271.8 billion CNY
- Sales value of newly built commercial buildings growth rate -13.1%
- Sales value of newly built residential buildings 375.4 billion CNY
- Self-raised funds for real estate development 1,654.4 billion CNY
Real Estate 41
Floor space of buildings for commercial business for sale growth rate -5% 0 pp since 31 Jul 2026 NBS China 2 records
Floor space of office buildings for sale growth rate 1% −0.6 pp since 31 Jul 2026 NBS China 2 records
Floor space of residential buildings for sale growth rate -0.5% −0.5 pp since 31 Jul 2026 NBS China 2 records
Show 36 more measures
- Foreign investment in real estate development enterprises growth rate -77%
- Sales of buildings for commercial business growth rate -19.1%
- Sales of office buildings growth rate -9.1%
- Deposits and advance receipts for real estate development 1,603.7 billion CNY
- Domestic loans for real estate development 688 billion CNY
- Floor space of buildings completed 211 million square meters
- Floor space of buildings for commercial business completed growth rate -30.8%
- Floor space of buildings for commercial business newly started growth rate -24.7%
- Floor space of buildings for commercial business under construction growth rate -12.7%
- Floor space of buildings newly started 298.9 million square meters
- Floor space of buildings under construction 5,607.7 million square meters
- Floor space of commercial buildings for sale 753.5 million square meters
- Floor space of commercial buildings for sale growth rate -0.8%
- Floor space of commercial buildings for sale held for less than three years 555.6 million square meters
- Floor space of commercial buildings sold (year to date) 498.8 million square meters
- Floor space of commercial buildings sold growth rate (year to date) -12.1%
- Floor space of existing housing online transactions 549.2 million square meters
- Floor space of existing housing online transactions year-over-year change 10.6%
- Floor space of newly built commercial buildings sold 498.8 million square meters
- Floor space of residential buildings completed 148 million square meters
- Floor space of residential buildings newly started 218.4 million square meters
- Floor space of residential buildings sold growth rate -12.7%
- Floor space of residential buildings under construction 3,893.5 million square meters
- Floor space of second-hand housing online transactions (year to date) 549.2 million square meters
- Funds for investment for real estate development enterprises growth rate -20.3%
- Individual mortgage loans for real estate development 684.6 billion CNY
- Investment in buildings for commercial business growth rate -25.5%
- Investment in office buildings growth rate -22%
- Investment in real estate development 4,797.9 billion CNY
- Investment in residential buildings 3,701.7 billion CNY
- Real estate investment growth rate (year to date) -19.9%
- Sales of commercial buildings (year to date) 4,747 billion CNY
- Sales of commercial buildings growth rate (year to date) -13%
- Sales of residential buildings growth rate -13.2%
- Sales value of newly built commercial buildings 4,747 billion CNY
- Self-raised funds for real estate development 1,843.2 billion CNY
Electric Vehicles 35
Show 30 more measures
- Electric truck sales share 70%
- Electric two- and three-wheeler sales share 30%
- New energy vehicle production 16.6 million
- Share of global electric car production 75%
- Share of global electric car sales 63%
- Automobile production (all powertrains) 34.5 million
- Average lithium-ion battery pack price 94 USD/kWh
- China NEV share of passenger car retail sales 65.2%
- Electric car fleet in circulation 44 million
- Electric car sales growth rate 40%
- Electric cars as a share of the car fleet 13%
- Electric light commercial vehicle sales 240 thousand
- Electric share of vehicle fleet 33%
- Electric three-wheeler sales 320 thousand
- Electric truck share of total truck sales 3%
- Electric two-wheeler sales 6 million
- Electric two-wheeler sales share of global market 78%
- New energy vehicle exports 2.62 million
- New energy vehicle sales 16.5 million
- New energy vehicle stock 44 million
- Oil demand displaced by electric vehicles 1 million barrels per day
- Public charging points added 850 thousand
- Public fast charging points 1.6 million
- Regional share of global electric car production 50%
- Regional share of global electric car sales 60%
- Share of global battery manufacturing capacity 80%
- Share of global battery recycling capacity 70%
- Share of global EV battery deployment 60%
- Share of world's fast EV chargers 85%
- Used electric car market size 800,000
Steel and Basic Metals 17
Angle steel market price 3,435.4 CNY per tonne +0.7% since 11 Aug 2026 to 20 Aug 2026 NBS China 2 records
Ferrous metal ores mining and processing producer price index growth (year-on-year) 1.1% NBS China 2 records
Show 12 more measures
- Ferrous metals smelting and pressing producer price index growth (year-on-year) -0.3%
- Rebar market price 3,130.3 CNY per tonne
- Steel demand growth -7.1%
- Steel exports 131 million tonnes
- Angle steel market price (CNY per tonne) 3,469.8 CNY per tonne
- Crude steel production (year to date) 415.5 million tonnes
- Crude steel production growth (year to date) -3.9%
- Planned capacity additions 38.6 million tonnes
- Rebar market price (CNY per tonne) 3,182.7 CNY per tonne
- Steel export growth 153%
- Steel export share of crude steel production 14%
- Steel industry total profits growth -51.2%
Public administration and defence; compulsory social security 1
Intentional homicides (per 100,000 people) 0.5 per 100,000 people −3.2% since 2019 World Bank 22 records
Airlines and Air Transport 12
Show 7 more measures
- Domestic airline RPK growth 12.3%
- Hainan Airlines domestic seat capacity 47.9 million seats
- Shenzhen Airlines domestic seat capacity 39.6 million seats
- Sichuan Airlines domestic seat capacity 38.8 million seats
- Top 3 airlines combined domestic seat capacity 341 million seats
- Top 3 airlines share of top 10 total capacity 58%
- Xiamen Airlines domestic seat capacity 37.8 million seats
Publishing 12
Show 7 more measures
- China game user scale 674 million
- China game user scale growth 0.94%
- China mini-program game market revenue 39.8 billion CNY
- China mobile game market actual sales revenue 238.2 billion CNY
- China mobile game revenue share 73.1%
- China self-developed game overseas market actual sales revenue 18.6 billion USD
- China self-developed game overseas market actual sales revenue growth 13.4%
Population 1
Chess 8
Show 3 more measures
Semiconductors 8
Show 3 more measures
Insurance 4
Oil and Gas 2
Logistics and Land Transport 3
Film and Video 1
579 measures. Each name opens the full series; each value opens the record with its source evidence.
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| 第57次《中国互联网络发展状况统计报告》（发布页摘要） Web page | CNNIC | T1 Official | 5 Feb 2026 | 29 Sep 2026 | 发布页摘要 | 9 |
| 第57次《中国互联网络发展状况统计报告》（全文PDF） Report | CNNIC | T1 Official | 5 Feb 2026 | 29 Sep 2026 | 报告正文; 表 5, PDF page 31: 2025.12 用户规模（万人）, 网络直播; 表 5, PDF page 31: 2024.12 用户规模（万人）, 网络直播 | 14 |
| 第56次《中国互联网络发展状况统计报告》（全文PDF） Report | CNNIC | T1 Official | 21 Jul 2025 | 29 Sep 2026 | 报告正文 | 8 |
| 第56次《中国互联网络发展状况统计报告》（发布页摘要） Web page | CNNIC | T1 Official | 21 Jul 2025 | 29 Sep 2026 | 发布页摘要 | 5 |
| 第55次《中国互联网络发展状况统计报告》（发布页摘要） Web page | CNNIC | T1 Official | 17 Jan 2025 | 29 Sep 2026 | 发布页摘要 | 4 |
| 第55次《中国互联网络发展状况统计报告》（全文PDF） Report | CNNIC | T1 Official | 17 Jan 2025 | 29 Sep 2026 | 报告正文 | 9 |
| China's 2024 air passenger traffic hits record high News article | CAAC | T1 Official | 3 Jan 2025 | 14 Sep 2026 | Paragraph 1 | 1 |
| China's air-passenger transport hits record high in 2024 News article | CAAC | T1 Official | 17 Dec 2024 | 14 Sep 2026 | Paragraph 3 | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
Showing the 40 documents with the most figures for China, of 232. Every record page names its own document; the full list is in the CSV download.
Cite this page
Data on this page is published under CC BY 4.0.
Region code CN is stable across the API and every hub.
StatOrigin. (2026). China industry statistics. Retrieved from https://statorigin.org/regions/china